Table 2.
Chemotherapies and endocrine therapies for the treatment of recurrent breast cancer for the two cohorts
| Cohort A (n = 170) |
Cohort B (n = 237) |
|||
|---|---|---|---|---|
| Therapy | No. of Patients | % | No. of Patients | % |
| Hormone therapy, % | ||||
| Tamoxifen | 65 | 38* | 62 | 26 |
| Medroxyprogesterone acetate | 80 | 47* | 35 | 15 |
| Aromatase inhibitors | 19 | 11* | 130 | 55 |
| Chemotherapy, % | ||||
| Anthracyclines | 81 | 48* | 51 | 22 |
| Taxanes | 43 | 25* | 110 | 46 |
| Vinorelbine | 4 | 2.4* | 60 | 25 |
| Capecitabine | 13 | 7.6* | 100 | 42 |
| Mitomycin | 82 | 49* | 2 | 0.8 |
| HER2 targeting therapy, % | ||||
| Trastuzumab | 5 | 2.9* | 51 | 22 |
*P < .05